Cardiovascular Disease patents
This page is updated frequently with new Cardiovascular Disease-related patent applications.
In which w, x and y have the meanings indicated in claim 1, are inhibitors of tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.. .
|Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds|
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
Aerie Pharmaceuticals, Inc.
|Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses|
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.
|Method and system for acquiring data for assessment of cardiovascular disease|
A method and system for acquiring data for assessment of cardiovascular disease, the method comprising one or more of: manipulating one or more hardware aspects of the photoplethysmography data acquisition system(s) implementing the method; manipulating or providing user experience/user interface (ux/ui) aspects of the system(s) implementing the method; acquiring, processing, and deriving insights population specific data; accounting for or controlling sampling site variability; and using other suitable sources of data in order to generate high quality data for characterization, assessment, and management of cardiovascular disease.. .
Vital Labs, Inc.
|High throughput biochemical fluorometric measuring hdl redox activity|
In various embodiments, a new, robust fluorometric cell-free biochemical assay that measures hdl redox activity (hra) is provided. In certain embodiments the assay is based on the oxidation of the fluorochrome amplex® red in the presence of hrp.
The Regents Of The University Of California
|Aplnr modulators and uses thereof|
The present invention provides apelin receptor (aplnr) modulators that bind to aplnr and methods of using the same. The invention includes aplnr modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate aplnr-mediated signaling.
Regeneron Pharmaceuticals, Inc.
|Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases|
The present application relates to novel 6-hydrogen-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. .
Bayer Pharma Aktiengesellschaft
|Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases|
The present application relates to novel heterocyclyl- and heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. .
Bayer Pharma Aktiengesellschaft
|Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases|
The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. .
Bayer Pharma Aktiengesellschaft
|Process for the synthesis of dabigatran etexilate and its intermediates|
The present invention describes an improved process for the preparation of dabigatran etexilate (formula-vii) or it's pharmaceutically acceptable salt for the treatment of thrombosis, cardiovascular diseases etc. And intermediates involved in the synthesis..
Biophore India Pharmaceuticals Pvt. Ltd.
Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
The disclosed subject matter provides certain n-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition.
The Johns Hopkins University
Mangifera indica as a sirtuin 1 activating agent
The invention relates to a mangifera (mango) indica preparation as sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developing obesity, type ii diabetes, elevated blood lipid levels, artheriosclerosis and cardiovascular diseases, as well as a cell and dna protector..
Vital Solutions Swiss Ag
Feed compositions comprising ricinodendron heudelotii and methods of processing and using thereof
The compositions, methods, and system of the invention provide increased nutrients and kidney size and reduced fat and risks of cardiovascular disease in animals by utilizing njangsa (ricinodendron heudelotii) as a feed and oral supplement for the animals.. .
Methods for diagnosing & treating copper-dependent diseases
Described are methods and materials for diagnosing a subject's predisposition for cardiovascular disease by detecting a copper deficiency genetic marker, as well as methods of alleviating cu transport impairment. Specifically, the cu deficiency genetic marker may be within the gene encoding a transmembrane cu transporter protein (ctri) or its regulatory sequences..
Modulation of angiopoietin-like 3 expression
Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal.
Ionis Pharmaceuticals, Inc.
Inhibitors of the renal outer medullary potassium channel
The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.
Systems and methods for delivering vagal nerve stimulation
According to various method embodiments, a person is indicated for a therapy to treat a cardiovascular disease, and the therapy is delivered to the person to treat the cardiovascular disease. Delivering the therapy includes delivering a vagal stimulation therapy (vst) to a vagus nerve of the person at a therapeutically-effective intensity for the cardiovascular disease that is below an upper boundary at which upper boundary the vst would lower an intrinsic heart rate during the vst..
Cardiac Pacemakers, Inc.
Novel macrocyclic compounds
The present invention relates to novel macrocyclic compounds of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft
Compositions and methods for treating neurodegenerative disease
The disclosure provides for compositions and methods for treating neurodegenerative and cardiovascular disease in a subject. The compositions and methods include delivering a nucleic acid molecule encoding vgf or a peptide thereof to a subject.
Myelin Therapeutics, Inc.
Dietary compositions for reducing blood glucose levels and for weight management
The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.
Methods for assessing the risk for development of cardiovascular disease
The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of hdl oxidation product. Measuring the quantity of one or more hdl oxidation products present in the blood is useful in evaluating risk for developing or evaluating the se verity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.
University Of Washington
Method for detecting cardiovascular disease biomarker
A method for analyzing concentration of a cardiovascular disease (cvd) biomarker in a liquid sample includes: applying the liquid sample to a biosensor, the biosensor including a transistor having a drain, a source, and a gate terminal disposed between the gate and the source, and a reactive electrode spaced apart from the gate terminal of the transistor and having a receptor immobilized thereon for specific binding with the cvd biomarker, the liquid sample being in contact with the gate terminal and the reactive electrode; applying a voltage pulse between the reactive electrode and the source, the voltage pulse having a pulse width; monitoring a response current in response to the voltage pulse; and analyzing the response current.. .
National Tsing Hua University
Oxidative stress and cardiovascular disease events
The present invention relates to diagnosis and/or prognosis of cardiovascular disease and cardiovascular events. A prognostic risk score in relation to the cardiovascular events, more particular after intervention, can be determined by counting the number of deregulated genes (or derived proteins) in their isolated monocytes.
Katholieke Universiteit Leuven
Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft
Sumoylation of serca2a and cardiovascular disease
Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of serca2a post-translation modification such as sumoylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting serca2a degradation.
Icahn School Of Medicine At Mount Sinai
Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis
The invention relates to compositions, formulations, vaccines and antibodies for the prevention and/or treatment of aging and brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification.
Compositions and methods for reducing chronic low-level inflammation
The invention relates to compositions and methods for reducing chronic low-level inflammation associated with chronic conditions. Specifically, the invention relates to compositions of hydrophobic derivatives of aspirin and/or hydrophobic derivatives of sesamol in combination with eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and their methods for reducing chronic low-level inflammation associated with chronic conditions including obesity, metabolic syndrome, diabetes, cardiovascular disease, cancer, auto-immune disorders, ocular and neurological disorders in a mammal..
Methods for analyzing rare circulating cells
The disclosure provides methods for analyzing rare circulating cells (rccs) at cellular and molecular level following their detection in non-enriched blood samples, methods of this disclosure serve as diagnostic methods for several disease conditions, including cardiovascular diseases and cancer.. .
Epic Sciences, Inc.
Uses of diazepane derivatives
The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Formula of neuregulin preparation
The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation.
Zensun (shanghai) Science & Technology, Co., Ltd.
In which r1 and r2 have the meanings indicated in claim 1, are inhibitors of tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.. .
5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft
Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
In some aspects, the present invention provides compounds of the formula (iv), wherein the variables are as defined herein, which may be used as inhibitors of histone demethylase or spermine oxidase. Also provided herein are pharmaceutical compositions of the compounds and methods using the compounds in the treatment of diseases such as cancer and cardiovascular disease..
Musc Foundation For Research Development
Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof
The present disclosure relates to the identification of pdk inhibitors and their use in the treatment of diseases such as diabetes, cardiovascular disease and cancer. The invention relates to the development of robust pdk inhibitors that can be used to improve glucose metabolism and correct metabolic dysfunction in vivo.
The Board Of Regents Of The University Of Texas System
Pcsk9 quantification by immunodetection
The present disclosure relates to, among other things, systems for detecting the level of specific lipoprotein-bound level of pcsk9, and optionally free pcsk9, lipoprotein or portions thereof and/or pcsk9 unbound lipoproteins present in a biological sample. The present invention also relates to methods of assessing the level of specific lipoprotein-bound level of pcsk9, and optionally free pcsk9, apo b and/or pcsk9 unbound lipoproteins present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease and monitoring the risk for developing cardiovascular disease..
True Health Diagnostics Llc
Concentrated therapeutic phospholipid compositions
The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and dieases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.. .
Acasti Pharma Inc.
Hormone treatment for age-related hearing loss-presbycusis
Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the us alone. There are currently no fda-approved drugs on the market in the us, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness.
University Of South Florida
Inhibitors of c-jun-n-terminal kinase (jnk)
Where ring a, ring b, x, l1, l2, ra, rc, rd, re, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases..
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cgmp-dependent phosphodiesterases.. .
Synergy Pharmaceuticals, Inc.
Lipidomic biomarkers for atherosclerosis and cardiovascular disease
The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or cvd by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and cvd than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or cvd.
Zora Biosciences Oy
Ultrasound molecular imaging with targeted biocompatible microbubbles
The present invention is related to cardiovascular contrast agents. In particular, compositions and methods for ultrasound cardiovascular contrast agents useful for molecular imaging and/or diagnosis of cardiovascular diseases and disorders.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Use of chec peptides to treat neurological and cardiovascular diseases and disorders
The present invention describes compositions and methods for treating and preventing non-degenerative neurological diseases and disorders associated with elevated spla2 activity as well as cardiovascular diseases using a chec peptide to inhibit spla2 activity.. .
Method and system for cardiovascular disease assessment and management
An embodiment of a method for assessing cardiovascular disease in a user with a body region using a mobile computing device including a camera module, includes receiving a time series of image data of a body region of the user, the time series of image data captured during a time period; generating a photoplethysmogram dataset from the time series of image data; generating a processed ppg dataset; determining a cardiovascular parameter value of the user based on the processed ppg dataset; fitting a chronobiological model to (1) the cardiovascular parameter value, and (2) a subsequent cardiovascular parameter value, characterizing a cardiovascular parameter variation over time of the user based on the fitted chronobiological model; and presenting an analysis of the cardiovascular parameter variation to the user at the mobile computing device.. .
Vital Labs, Inc.
Saxatilin-fc fusion protein and use thereof
The present invention relates to a saxatilin derivative having an increased half life and a use thereof. The saxatilin derivative of the present invention has thrombolytic ability similar to that of saxatilin, which is the mother protein, a remarkably increased protein half life, and efficiently dissolves, for long period of time, blood clots already formed in blood vessels of an animal model with a fecl3-induced carotid by using the same.
Industry-academic Cooperation Foundation, Yonsei University
Biomarkers for cardiovascular disease
Described herein are methods for diagnosing or assessing and treating an individual for cardiovascular disease based on the individual's normalized level of biomarkers. For example, a level of lp-pla2 mass or lp-pla2 activity normalized to a level of lp-pla2 total mass (e.g.
Trimethylamine compounds as risk predictors of cardiovascular disease
Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine n-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value.
The Cleveland Clinic Foundation
Dihydropteridinone derivatives and uses thereof
The present invention provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Diazepane derivatives and uses thereof
The present invention provides compounds of any one of formulae (i), (ii-c) (e.g., formula (ii)), and (iii), and pharmaceutically compositions thereof. Compounds of any one of formulae (i), (ii-c), and (iii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Apparatus and treating cardiovascular diseases
A removable apparatus is provided for temporary implantation in a pulmonary vein for ablating atrial tissue surrounding the antrum of the pulmonary vein to treat atrial fibrillation in a subject. The apparatus comprises an electrically-insulated expandable support member and a retrieval mechanism.
The Cleveland Clinic Foundation
Detection of insulin resistance, diabetes, cardiovascular disease and autonomic neuropathy
A method and system for detecting insulin resistance, diabetes, cardiovascular disease and/or autonomic neuropathy in a patient is provided. The method includes measuring a photoplethysmogram (ptg) and galvanic skin response from the patient, executing a spectral analysis on the ptg, comparing values derived from the ptg and the galvanic skin response of the patient to stored clinical data, calculating a ptg cardiovascular risk score based on the comparison, comparing further derived values to predefined values that correspond to certain diseases, including insulin resistance, diabetes, cardiovascular disease and autonomic neuropathy, and displaying the ptg cardiovascular risk score and said certain diseases that correspond to said predefined values..
Medical Screening Corporation
Ketohexokinase (khk) irna compositions and methods of use thereof
The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.
Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
The present invention relates to compositions and methods for treatment and/or prevention of a cardiovascular disease. In one embodiment, the invention provides compositions and methods for decreasing one or more of the level, production, and activity of ezh2..
University Of Rochester
Cardiovascular Disease topics:
Pharmaceutically Acceptable Salt
Follow us on Twitter
This listing is a sample listing of patent applications related to Cardiovascular Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cardiovascular Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.